Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 7Thoracic 5Plasma cell 4Endocrine 2CNS 2Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Neuroendocrine Tumors 32Multiple Endocrine Neoplasia Type 1 9Neoplasms 8Pituitary Neoplasms 7Carcinoid Tumor 7Pituitary ACTH Hypersecretion 6Gastro-enteropancreatic neuroendocrine tumor 6Differentiated Thyroid Cancer 6Adrenocortical Carcinoma 6Thyroid Cancer, Papillary 5Pituitary Diseases 5Pheochromocytoma 5Thyroid Neoplasms 4Serotonin Syndrome 4Neuroblastoma 4Cushing Syndrome 4Breast Neoplasms 4Acromegaly 4ACTH Syndrome, Ectopic 4Sarcoma 3Liposarcoma 3Insulinoma 3Fibrosarcoma 3Endometrial Neoplasms 3Carcinoma, Medullary 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Parkinson Disease 2

Interventions

3-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Disease × Endocrine × Clear all
NCT00171873 2020-03-26

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Philipps University Marburg

Phase 3 Completed
85 enrolled 6 charts
EndocrineNET

Disease, Neoplasms, Neuroendocrine Tumors

NCT00126412 2019-05-31

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

GE Healthcare

Phase 3 Completed
251 enrolled
CNSEndocrine

Disease, Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡